SCM
CPRX icon

Segantii Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Segantii Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,700
Closed -$13K – 101
2017
Q1 		$13K Buy
+6,700
New +$8.54K ﹤0.01% 365

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Segantii Capital Management's CPRX Position: Q2 2017 in Review

Segantii Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2017, closing a stake of 6,700 shares — an estimated $13K sold.

Segantii Capital Management first reported a position in CPRX in Q1 2017 and held it in 1 quarter. The position peaked at $13K in Q1 2017. 69 funds tracked by Wall St. Rank hold CPRX as of Q2 2017.

  • Segantii Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 6,700 Catalyst Pharmaceutical shares in Q2 2017, an estimated $13K.
  • Segantii Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Catalyst Pharmaceutical position peaked at $13K in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.